Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Common Equity (2016 - 2025)

Avanos Medical's Common Equity history spans 12 years, with the latest figure at $1.2 billion for Q3 2024.

  • For Q3 2024, Common Equity rose 0.62% year-over-year to $1.2 billion; the TTM value through Sep 2024 reached $1.2 billion, up 0.62%, while the annual FY2023 figure was $1.2 billion, 4.25% down from the prior year.
  • Common Equity for Q3 2024 was $1.2 billion at Avanos Medical, up from -$98.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.6 billion in Q2 2022 and bottomed at -$287.6 million in Q2 2020.
  • The 5-year median for Common Equity is $1.2 billion (2023), against an average of $773.0 million.
  • The largest annual shift saw Common Equity tumbled 762.42% in 2020 before it soared 552.61% in 2021.
  • A 5-year view of Common Equity shows it stood at $1.3 billion in 2020, then grew by 0.67% to $1.3 billion in 2021, then rose by 1.62% to $1.3 billion in 2022, then fell by 4.25% to $1.2 billion in 2023, then dropped by 0.53% to $1.2 billion in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Common Equity are $1.2 billion (Q3 2024), -$98.5 million (Q2 2024), and -$29.5 million (Q1 2024).